RootPath Raises $11 Million Series A to Accelerate Clinical Translation of its Proprietary Synthetic Immunology Platform

生物科技公司RootPath完成1100万美元A轮融资,经纬中国、元禾原点共同领投

2020-01-07 10:53:08 CISION

本文共1126个字,阅读需3分钟

 RootPath, a preclinical-stage biotechnology company aiming to enable personalized, highly-potent T cell therapy powered by its proprietary Synthetic Immunology Platform™, today announced a $11 million Series A funding round.  New investors include Oriza Seed with participation from existing investors Sequoia Capital China, Volcanics Venture, BV and Nest.Bio Ventures.  The company will use the Series A proceeds to validate its tumor-reactive T cell receptor discovery workflow, select a lead therapeutic candidate, demonstrate its safety and efficacy in preclinical models and begin IND-enabling development activities. Launched in 2017 by Nest.Bio Ventures, RootPath has developed a suite of proprietary technologies that comprise its Synthetic Immunology Platform™ to rapidly and inexpensively recreate T cell immune repertoires and to emulate their antigen-driven selection process in vitro.  The Synthetic Immunology Platform™ centers on the rapid and ultrahigh-throughput generation and functional selection of TCRs, and forms the basis of the personalized T cell therapy that RootPath is advancing. The company had previously announced a $7 M seed round in 2018 led by Sequoia Capital China. Cell therapies such as chimeric antigen receptor (CAR) therapies have delivered notable successes in hematological malignancies.  "The hurdle to achieving effective cell therapies for solid tumors has been identifying safe and effective tumor-reactive agents for these T cells, either as CAR or TCR," said Xi Chen, Ph.D., co-founder and CEO.  "Because of the way T cells recognize tumors, discovering tumor-reactive agents for each individual patient or each sub-population of patients has been economically infeasible using existing technologies.  This is why we spent the past two years developing our proprietary Synthetic Immunology Platform, which takes advantage of many breakthroughs in synthetic biology and overcomes many intrinsic challenges in immunology-oriented research and drug discovery." "We are excited to have the support from our new and existing investors to move from technology development to therapeutic translation of our platform," Chen continued. "Solid tumors are substantially more challenging than hematological malignancies, but, at the same time, represent a more attractive and valuable market," said Grace Yang, Partner of Oriza Seed.  "The unique approach RootPath takes effectively creates T cells armed with more targeted weapons, which should translate to increased efficacy and reduced toxicity to patients.  We are confident in the Synthetic Immunology Platform, and look forward its clinical translation as well as synergy with potential product candidates from other companies in our existing immuno-oncology portfolio." About RootPathRootPath is a preclinical-stage biotechnology company pioneering personalized immunotherapy and cell therapy for solid tumors using its proprietary Synthetic Immunology Platform™. RootPath was launched by Nest.Bio Ventures in 2017 and has raised $18M in seed and Series A financing.  RootPath is located  in Cambridge, MA with additional research activities at two sites in China. SOURCE RootPath Related Links https://www.rootpath.com
RootPath 是一家临床前阶段的生物技术公司,旨在利用其专有的合成免疫平台™实现个性化、高效的 T 细胞治疗,今天宣布了一轮1100万美元的 A 系列融资。新投资者包括 Oriza Seed ,现有投资者 Sequoia Capital China 、 Volcanics Ventures 、 BV 和 Nest 参与其中。生物风险投资.公司将利用 A 系列募集资金验证其肿瘤活性 T 细胞受体发现工作流程,选择领先的治疗候选者,在临床前模型中展示其安全性和有效性,并开始 IND 授权开发活动。 雀巢公司于2017年推出。生物风险投资公司 RootPath 开发了一套专有技术,包括其合成免疫平台™以快速和廉价地再现 T 细胞免疫曲目并在体外模拟其抗原驱动的选择过程。合成免疫平台™以 TCR 的快速、超高通量产生和功能选择为核心,形成了 RootPath 正在推进的个性化 T 细胞治疗的基础。该公司此前曾在2018年宣布以红杉资本中国( Sequoia Capital China )为首的一轮700万美元的种子融资。 嵌合抗原受体( CAR )等细胞治疗在血液肿瘤方面取得了显著的成功。“实现实体肿瘤有效的细胞治疗的障碍在于为这些 T 细胞寻找安全有效的肿瘤反应剂,无论是 CAR 还是 TCR ,”联合创始人兼首席执行官陈曦博士说。“由于 T 细胞识别肿瘤的方式,为每一个病人或每一个病人的亚群体发现肿瘤反应因子在经济上是不可行的,使用现有技术。这就是为什么我们花了两年时间开发我们的专有合成免疫平台,利用合成生物学的许多突破,克服了免疫学导向研究和药物发现的许多内在挑战。 “我们很高兴得到新投资者和现有投资者的支持,从技术开发转向我们平台的治疗翻译,”陈继续说。 Oriza Seed 的合伙人 Grace Yang 说:“实体肿瘤远比血液肿瘤更具挑战性,但同时也是一个更具吸引力和价值的市场。”“ RootPath 独特的方法有效地创造了 T 细胞携带更有针对性的武器,这将提高疗效并减少对患者的毒性。我们对合成免疫学平台充满信心,期待其临床翻译以及与现有免疫肿瘤组合中其他公司潜在产品候选人的协同效应。 关于 RootPathRootPathPath 是一家临床前阶段的生物技术公司,利用其专有的合成免疫平台™开创了针对实体肿瘤的个性化免疫治疗和细胞治疗。RootPath 由 Nest 启动。生物创投于2017年已募集资金1800万美元用于种子和 A 系列融资。RootPath 位于美国马萨诸塞州剑桥市,在中国的两个地方开展了额外的研究活动。 SOURCE 根路径 相关链接 https://www.rootpath.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文